87 results on '"Hymes, J."'
Search Results
2. SUN-183 DIURNAL RHYTHMS OF SERUM PHOSPHATE IN HEMODIALYSIS PATIENTS
- Author
-
Larkin MS, J., primary, Chen, C., additional, Jiao, Y., additional, Winter, A., additional, Usvyat, L., additional, Stauss-Grabo, M., additional, Hymes, J., additional, and Maddux, F., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Processing of Non-Conjugative Resistance Plasmids by Conjugation Nicking Enzyme of Staphylococci.
- Author
-
Pollet, R., Ingle, J., Hymes, J., Eakes, T., Eto, K., Kwong, S., Ramsay, Joshua, Firth, N., Redinbo, M., Pollet, R., Ingle, J., Hymes, J., Eakes, T., Eto, K., Kwong, S., Ramsay, Joshua, Firth, N., and Redinbo, M.
- Abstract
Antimicrobial resistance in Staphylococcus aureus presents an increasing threat to human health. This resistance is often encoded on mobile plasmids, such as pSK41; however, the mechanism of transfer of these plasmids is not well understood. In this study, we first examine key protein-DNA interactions formed by the relaxase enzyme, NES, which initiates and terminates the transfer of the multidrug resistance plasmid pSK41. Two loops on the NES protein, hairpin loops 1 and 2, form extensive contacts with the DNA hairpin formed at the oriT region of pSK41, and here we establish that these contacts are essential for proper DNA cleavage and religation by the full 665-residue NES protein in vitro. Second, pSK156 and pCA347 are nonconjugative Staphylococcus aureus plasmids that contain sequences similar to the oriT region of pSK41 but differ in the sequence predicted to form a DNA hairpin. We show that pSK41-encoded NES is able to bind, cleave, and religate the oriT sequences of these nonconjugative plasmids in vitro. Although pSK41 could mobilize a coresident plasmid harboring its cognate oriT, it was unable to mobilize plasmids containing the pSK156 and pCA347 variant oriT mimics, suggesting that an accessory protein like that previously shown to confer specificity in the pWBG749 system may also be involved in transmission of plasmids containing a pSK41-like oriT. These data indicate that the conjugative relaxase in trans mechanism recently described for the pWBG749 family of plasmids also applies to the pSK41 family of plasmids, further heightening the potential significance of this mechanism in the horizontal transfer of staphylococcal plasmids.IMPORTANCE Understanding the mechanism of antimicrobial resistance transfer in bacteria such as Staphylococcus aureus is an important step toward potentially slowing the spread of antimicrobial-resistant infections. This work establishes protein-DNA interactions essential for the transfer of the Staphylococcus aureus multiresist
- Published
- 2016
4. Child care problems of the night shift mother
- Author
-
Hymes, J. L., Jr.
- Published
- 1944
5. Biochemical and immunological characterization of serum biotinidase in profound biotinidase deficiency
- Author
-
Hart, P S, Hymes, J, and Wolf, B
- Subjects
Adult ,Male ,Biotinidase ,Blotting, Western ,food and beverages ,Cross Reactions ,Amidohydrolases ,Substrate Specificity ,Isoenzymes ,Kinetics ,Reference Values ,Humans ,Female ,Isoelectric Focusing ,Child ,Research Article - Abstract
The biochemical and immunological characterization of biotinidase was performed in sera from 100 normal individuals, 68 children with profound biotinidase deficiency (less than 10% of mean normal activity) who were identified symptomatically and by newborn screening, and 63 of their parents. On isoelectric focusing, serum enzyme from normal individuals exhibits extensive microheterogeneity, consisting of at least four major and five minor isoforms at pH 4.15-4.35. Patients with profound biotinidase deficiency can be classified into at least nine distinct biochemical phenotypes, on the basis of (a) the presence or absence of cross-reacting material (CRM) to biotinidase, (b) the number of isoforms, and (c) the distribution frequency of the isoforms. None of the patients with CRM had an abnormal Km of the substrate for the enzyme. All of the parents had normal isoform patterns. The mean activities, CRM concentrations, and specific activities were not significantly different between parents of CRM-positive children and parents of CRM-negative children. There is no relationship between either the age at onset or the severity of symptoms and the isoform patterns or CRM status of the symptomatic children. The isoform patterns of children identified by newborn screening are not different from those of symptomatic children.
- Published
- 1992
6. The use of biotinylated compounds or reagents is much more complicated than originally thought
- Author
-
Hymes, J., primary and Wolf, B., additional
- Published
- 2000
- Full Text
- View/download PDF
7. Amino Acid Homologies between Human Biotinidase and Bacterial Aliphatic Amidases: Putative Identification of the Active Site of Biotinidase
- Author
-
Swango, K.L., primary, Hymes, J., additional, Brown, P., additional, and Wolf, B., additional
- Published
- 2000
- Full Text
- View/download PDF
8. Prenatal diagnosis of heterozygosity for biotinidase deficiency by enzymatic and molecular analyses
- Author
-
Pomponio, R. J., primary, Hymes, J., additional, Pandya, A., additional, Landa, B., additional, Melone, P., additional, Javaheri, R., additional, Mardach, R., additional, Morton, S. W., additional, Meyers, G. A., additional, Reynolds, T., additional, Buck, G., additional, Nance, W. E., additional, and Wolf, B., additional
- Published
- 1998
- Full Text
- View/download PDF
9. Angiotensin in progressive renal diseases
- Author
-
Matsusaka, T, primary, Hymes, J, additional, and Ichikawa, I, additional
- Published
- 1996
- Full Text
- View/download PDF
10. Biotinylation of Histones by Human Serum Biotinidase: Assessment of Biotinyl-Transferase Activity in Sera from Normal Individuals and Children with Biotinidase Deficiency
- Author
-
Hymes, J., primary, Fleischhauer, K., additional, and Wolf, B., additional
- Published
- 1995
- Full Text
- View/download PDF
11. Human serum biotinidase. cDNA cloning, sequence, and characterization.
- Author
-
Cole, H., primary, Reynolds, T.R., additional, Lockyer, J.M., additional, Buck, G.A., additional, Denson, T., additional, Spence, J.E., additional, Hymes, J., additional, and Wolf, B., additional
- Published
- 1994
- Full Text
- View/download PDF
12. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
- Author
-
Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, and Tak Piech C
- Abstract
OBJECTIVE: To compare real-world dosing patterns, drug costs, and hematologic outcome in anemic chronic kidney disease (CKD) patients, not receiving dialysis, who switched from darbepoetin alfa (DARB) to epoetin alfa (EPO) in a community practice setting. RESEARCH DESIGN AND METHODS: This retrospective observational chart review from a US nephrology clinic included 153 anemic CKD patients > or = 18 years of age who did not receive dialysis during the study period, switched from DARB to EPO between 8/2003 and 8/2005, and received > or = 2 doses of both agents. Paired t-test and McNemar's chi-square were performed comparing pre-switch and post-switch outcomes. RESULTS: Mean interval between doses increased from 24.3 +/- 11.1 days with DARB to 28.8 +/- 19.8 days with EPO (p = 0.001). Weighted mean pre-switch weekly dose for DARB was 25 mug, while weighted mean post-switch weekly dose for EPO was 7090 Units, resulting in a dose ratio (Units EPO:microg DARB) of 287:1. These doses resulted in mean weekly costs of $110 (DARB) and $86 (EPO). Mean hemoglobin (Hb) levels increased over time from 10.8 g/dL at 6 months pre-switch to 11.1 g/dL 6 months after EPO initiation (p = 0.0132). Mean Hb levels were > 11 g/dL, but below 12 g/dL, while patients received EPO. CONCLUSIONS: Patients switching from DARB to EPO had a greater mean interval between doses, lower drug costs, and consistently maintained recommended Hb levels over time. LIMITATIONS: The reverse direction (EPO to DARB) was not investigated. Although treatment outcomes were not assessed in a randomized, controlled setting, the study's observational nature provided actual evidence in a real-world setting. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. 2004 annual report of the American Chiropractic Association.
- Author
-
Cuneo GF, Feather-Clancy F, Jackson PS, Wanda J, and Hymes J
- Abstract
The executive vice president and each of the departmental vice presidents provide insights into the many ACA activities that helped advance chiropractic during the past 12 months. [ABSTRACT FROM AUTHOR]
- Published
- 2004
14. Human biotinidase isn't just for recycling biotin.
- Author
-
Hymes, Jeanne, Wolf, Barry, Hymes, J, and Wolf, B
- Subjects
PROTEIN metabolism ,BIOTIN metabolism ,AMIDASES ,BIOLOGICAL transport ,COENZYMES ,COMPARATIVE studies ,HYDROLASES ,MOLECULAR probes ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,EVALUATION research - Abstract
For years, the major role of biotin has been as the coenzyme for four carboxylases in humans. Although there has been evidence that biotin might have other functions, none has been firmly established. The discovery that human serum biotinidase has biotinyl-transferase activity, in addition to biotinidase hydrolase activity, presents new possibilities for the role of biotinidase in biotin metabolism. Specific transfer of biotin to histones by biotinidase provides a possible explanation for why biotin is found in the nucleus and the nature of its role in the regulation of protein transcription. Future studies will help to determine the functions of biotinidase in biotin metabolism and in disease states. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
15. Neurogenic bladder dysfunction as a complication of diabetes; report of seven cases.
- Author
-
SPRING, M and HYMES, J
- Published
- 1953
- Full Text
- View/download PDF
16. Pneumaturia; report of a case in a diabetic with review of the literature.
- Author
-
SPRING, M and HYMES, J J
- Published
- 1952
- Full Text
- View/download PDF
17. Delayed-onset profound biotinidase deficiency
- Author
-
Wolf, B., Pomponio, R.J., Norrgard, K.J., Lott, I.T., Baumgartner, E., Suormala, T., Ramaekers, V.Th., Coskun, T., Tokatli, A., Ozalp, I., and Hymes, J.
- Abstract
Children with biotinidase deficiency usually exhibit symptoms at several months to years of age. We describe four children who had symptoms later in childhood or during adolescence; they had motor limb weakness, spastic paresis, and eye problems, such as loss of visual acuity and scotomata, rather than the more characteristic symptoms observed in young untreated children with the disorder. These older children each have different mutations, but they are the same as those of children who have exhibited symptoms at an early age. Biotinidase deficiency should be considered in older children who suddenly experience limb weakness and/or spastic paresis and eye symptoms. (J Pediatr 1998;132:362-5)
- Published
- 1998
- Full Text
- View/download PDF
18. Biotinidase and its roles in biotin metabolism
- Author
-
Hymes, J. and Wolf, B.
- Published
- 1996
- Full Text
- View/download PDF
19. Cost effectiveness of outpatient management of cancer pain by patient controlled analgesia (P.C.A) devices
- Author
-
Hymes, J. A., primary and Lamnin, M. A., additional
- Published
- 1987
- Full Text
- View/download PDF
20. Adirondack Voices: Woodsmen and WoodsLore. By Robert D. Bethke. Urbana: University of Illinois Press, 1981. 148 pp. Hardbound, $12.50.
- Author
-
Hymes, J. J., primary
- Published
- 1982
- Full Text
- View/download PDF
21. Child care problems of the night shift mother.
- Author
-
Hymes, J. L., primary
- Published
- 1944
- Full Text
- View/download PDF
22. Biotinylation of biotinidase following incubation with biocytin
- Author
-
Hymes, J., Fleischhauer, K., and Wolf, B.
- Published
- 1995
- Full Text
- View/download PDF
23. Editor's Choice - Challenges of Predicting Arteriovenous Access Survival Prior to Conversion from Catheter.
- Author
-
Hofmann AG, Lama S, Zhang H, Assadian A, Sor M, Hymes J, Kotanko P, and Raimann J
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Machine Learning, Risk Assessment, Risk Factors, Clinical Decision-Making, Time Factors, Arteriovenous Shunt, Surgical adverse effects, Renal Dialysis
- Abstract
Objective: The decision to convert from catheter to arteriovenous access is difficult yet very important. The ability to accurately predict fistula survival prior to surgery would significantly improve the decision making process. Many previously investigated demographic and clinical features have been associated with fistula failure. However, it is not conclusively understood how reliable predictions based on these parameters are at an individual level. The aim of this study was to investigate the probability of arteriovenous fistula maturation and survival after conversion using machine learning workflows., Methods: A retrospective cohort study on multicentre data from a large North American dialysis organisation was conducted. The study population comprised 73 031 chronic in centre haemodialysis patients. The dataset included 49 variables including demographic and clinical features. Two distinct feature selection and prediction pipelines were used: LASSO regression and Boruta followed by a random forest classifier. Predictions were facilitated for re-conversion to catheter within one year. Additionally, all cause mortality predictions were conducted to serve as a comparator., Results: In total, 38 151 patients (52.2%) had complete data and made up the main cohort. Sensitivity analyses were conducted in 67 421 patients (92.3%) after eliminating variables with a high proportion of missing data points. Selected features diverged between datasets and workflows. A previously failed arteriovenous access appeared to be the most stable predictor for subsequent failure. Prediction of re-conversion based on the demographic and clinical information resulted in an area under the receiver operating characteristic curve (ROCAUC) between 0.541 and 0.571, whereas models predicting all cause mortality performed considerably better (ROCAUC 0.662 - 0.683)., Conclusion: While group level depiction of major adverse outcomes after catheter to arteriovenous fistula or graft conversion is possible using the included variables, patient level predictions are associated with limited performance. Factors during and after fistula creation as well as biomolecular and genetic biomarkers might be more relevant predictors of fistula survival than baseline clinical conditions., (Copyright © 2024 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
- Author
-
Larkin J, Hymes J, Britton ML, Oluwatosin Y, Nolen J, Zhu L, and Silva A
- Subjects
- Humans, Renal Dialysis, Hemoglobins analysis, Glycine adverse effects, Isoquinolines therapeutic use, Isoquinolines adverse effects, Anemia drug therapy, Anemia etiology, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Hematinics therapeutic use, Hematinics adverse effects
- Abstract
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in several regions for the treatment of anemia of chronic kidney disease (CKD). DENALI, a phase 3b study, evaluated the efficacy, safety, and feasibility of roxadustat in patients with anemia of CKD receiving in-center or home dialysis., Methods: Eligible patients received open-label roxadustat, dosed three times weekly for 24 weeks, with an optional extension of ≤1 year. Initial dosing depended on erythropoiesis-stimulating agent (ESA) dose at screening for patients receiving ESAs (≥6 weeks) and weight-based for those not (total <6 weeks). Primary efficacy endpoints were proportion of patients with mean hemoglobin (Hb) ≥10.0 g/dL averaged over Weeks 16-24, and mean Hb change from baseline to the average during Weeks 16-24. Treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) were assessed., Findings: Of 281 patients screened, 203 were treated and 201 included in the full analysis set. Overall, 166 patients completed the 24-week treatment period and 126 continued into the extension period. Mean baseline Hb was 10.4 g/dL and 82.6% received in-center hemodialysis. Overall, 84.6% of patients achieved a mean Hb ≥ 10.0 g/dL averaged Weeks 16-24. Mean (standard deviation) Hb change from baseline averaged Weeks 16-24 was 0.5 (1.0) g/dL. Prespecified subgroup analyses were consistent with primary analyses. Dosing adherence was 94%. Overall, 3.0% of patients received a red blood cell transfusion at up to Week 24. TEAEs and TESAEs were reported by 71.4% and 25.6% of patients, respectively. The most frequently reported TESAEs were COVID-19 (n = 5; 2.5%), and acute myocardial infarction, pneumonia, and sepsis (each n = 4; 2.0%)., Discussion: Roxadustat effectively achieved and/or maintained mean Hb levels ≥10.0 g/dL in patients receiving dialysis. The feasibility of incorporating oral roxadustat into dialysis organizations was successfully demonstrated with high dosing adherence. No new safety signals were identified., (© 2023 The Authors. Hemodialysis International published by Wiley Periodicals LLC on behalf of International Society for Hemodialysis.)
- Published
- 2024
- Full Text
- View/download PDF
25. Effectiveness of cold HD for the prevention of HD hypotension and mortality in the general HD population.
- Author
-
Zoccali C, Tripepi G, Neri L, Savoia M, Baró Salvador ME, Ponce P, Hymes J, Maddux F, Mallamaci F, and Stuard S
- Subjects
- Humans, Renal Dialysis adverse effects, Renal Dialysis methods, Blood Pressure, Dialysis Solutions, Hypotension etiology, Hypotension prevention & control, Kidney Failure, Chronic therapy, Kidney Failure, Chronic complications
- Abstract
Background: Cold hemodialysis (HD) prevented intradialysis hypotension (IDH) in small, short-term, randomized trials in selected patients with IDH. Whether this treatments prevents IDH and mortality in the HD population at large is unknown., Methods: We investigated the relationship between dialysate temperature and the risk of IDH, i.e. nadir blood pressure <90 mmHg (generalized estimating equation model) and all-cause mortality (Cox's regression) in an incident cohort of HD patients (n = 8071). To control for confounding by bias by indication and other factors we applied instrumental variables adjusting for case mix at facility level., Results: Twenty-seven percent of patients in the study cohort were systematically treated with a dialysate temperature ≤35.5°C. Over a median follow-up of 13.6 months (interquartile range 5.2-26.1 months), a 0.5°C reduction of the dialysate temperature was associated with a small (-2.4%) reduction of the risk of IDH [odds ratio (OR) 0.976, 95% confidence interval (CI) 0.957-0.995, P = .013]. In case-mix, facility-level adjusted analysis, the association became much stronger (OR 0.67, 95% CI 0.63-0.72, risk reduction = 33%, P < .001). In contrast, colder dialysate temperature had no effect on mortality both in the unadjusted [hazard ratio (HR) (0.5°C decrease) 1.074, 95% CI 0.972-1.187, P = .16] and case-mix-adjusted analysis at facility level (HR 1.01, 95% CI 0.88-1.16, P = .84). Similar results were registered in additional analyses by instrumental variables applying the median dialysate temperature or the facility percentage of patients prescribed a dialysate temperature <36°C. Further analyses restricted to patients with recurrent IDH fully confirmed these findings., Conclusions: Cold HD was associated with IDH in the HD population but had no association with all-cause mortality., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
26. Virtual Screening for the Discovery of Microbiome β-Glucuronidase Inhibitors to Alleviate Cancer Drug Toxicity.
- Author
-
Challa AP, Hu X, Zhang YQ, Hymes J, Wallace BD, Karavadhi S, Sun H, Patnaik S, Hall MD, and Shen M
- Subjects
- Early Detection of Cancer, Enzyme Inhibitors pharmacology, Glycoproteins, Humans, Antineoplastic Agents adverse effects, Drug-Related Side Effects and Adverse Reactions, Microbiota, Neoplasms
- Abstract
Despite the potency of most first-line anti-cancer drugs, nonadherence to these drug regimens remains high and is attributable to the prevalence of "off-target" drug effects that result in serious adverse events (SAEs) like hair loss, nausea, vomiting, and diarrhea. Some anti-cancer drugs are converted by liver uridine 5'-diphospho-glucuronosyltransferases through homeostatic host metabolism to form drug-glucuronide conjugates. These sugar-conjugated metabolites are generally inactive and can be safely excreted via the biliary system into the gastrointestinal tract. However, β-glucuronidase (βGUS) enzymes expressed by commensal gut bacteria can remove the glucuronic acid moiety, producing the reactivated drug and triggering dose-limiting side effects. Small-molecule βGUS inhibitors may reduce this drug-induced gut toxicity, allowing patients to complete their full course of treatment. Herein, we report the discovery of novel chemical series of βGUS inhibitors by structure-based virtual high-throughput screening (vHTS). We developed homology models for βGUS and applied them to large-scale vHTS against nearly 400,000 compounds within the chemical libraries of the National Center for Advancing Translational Sciences at the National Institutes of Health. From the vHTS results, we cherry-picked 291 compounds via a multifactor prioritization procedure, providing 69 diverse compounds that exhibited positive inhibitory activity in a follow-up βGUS biochemical assay in vitro . Our findings correspond to a hit rate of 24% and could inform the successful downstream development of a therapeutic adjunct that targets the human microbiome to prevent SAEs associated with first-line, standard-of-care anti-cancer drugs.
- Published
- 2022
- Full Text
- View/download PDF
27. Trajectories of clinical and laboratory characteristics associated with COVID-19 in hemodialysis patients by survival.
- Author
-
Chaudhuri S, Lasky R, Jiao Y, Larkin J, Monaghan C, Winter A, Neri L, Kotanko P, Hymes J, Lee S, Wang Y, Kooman JP, Maddux F, and Usvyat L
- Subjects
- Adult, Blood Pressure, Humans, Laboratories, Renal Dialysis, SARS-CoV-2, COVID-19
- Abstract
Introduction: The clinical impact of COVID-19 has not been established in the dialysis population. We evaluated the trajectories of clinical and laboratory parameters in hemodialysis (HD) patients., Methods: We used data from adult HD patients treated at an integrated kidney disease company who received a reverse transcription polymerase chain reaction (RT-PCR) test to investigate suspicion of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection between May 1 and September 1, 2020. Nonparametric smoothing splines were used to fit data for individual trajectories and estimate the mean change over time in patients testing positive or negative for SARS-CoV-2 and those who survived or died within 30 days of first suspicion or positive test date. For each clinical parameter of interest, the difference in average daily changes between COVID-19 positive versus negative group and COVID-19 survivor versus nonsurvivor group was estimated by fitting a linear mixed effects model based on measurements in the 14 days before (i.e., Day -14 to Day 0) Day 0., Results: There were 12,836 HD patients with a suspicion of COVID-19 who received RT-PCR testing (8895 SARS-CoV-2 positive). We observed significantly different trends (p < 0.05) in pre-HD systolic blood pressure (SBP), pre-HD pulse rate, body temperature, ferritin, neutrophils, lymphocytes, albumin, and interdialytic weight gain (IDWG) between COVID-19 positive and negative patients. For COVID-19 positive group, we observed significantly different clinical trends (p < 0.05) in pre-HD pulse rate, lymphocytes, neutrophils, and albumin between survivors and nonsurvivors. We also observed that, in the group of survivors, most clinical parameters returned to pre-COVID-19 levels within 60-90 days., Conclusion: We observed unique temporal trends in various clinical and laboratory parameters among HD patients who tested positive versus negative for SARS-CoV-2 infection and those who survived the infection versus those who died. These trends can help to define the physiological disturbances that characterize the onset and course of COVID-19 in HD patients., (© 2021 The Authors. Hemodialysis International published by Wiley Periodicals LLC on behalf of International Society for Hemodialysis.)
- Published
- 2022
- Full Text
- View/download PDF
28. Transmission of SARS-CoV-2 considering shared chairs in outpatient dialysis: a real-world case-control study.
- Author
-
Thadhani R, Willetts J, Wang C, Larkin J, Zhang H, Fuentes LR, Usvyat L, Belmonte K, Wang Y, Kossmann R, Hymes J, Kotanko P, and Maddux F
- Subjects
- Aged, COVID-19 epidemiology, Case-Control Studies, Environmental Exposure, Female, Humans, Infection Control methods, Logistic Models, Male, Middle Aged, Models, Theoretical, Retrospective Studies, Risk, SARS-CoV-2, United States epidemiology, Ambulatory Care Facilities, COVID-19 transmission, Fomites virology, Interior Design and Furnishings, Outpatients, Renal Dialysis, Virus Shedding
- Abstract
Background: SARS-CoV-2 can remain transiently viable on surfaces. We examined if use of shared chairs in outpatient hemodialysis associates with a risk for indirect patient-to-patient transmission of SARS-CoV-2., Methods: We used data from adults treated at 2,600 hemodialysis facilities in United States between February 1st and June 8th, 2020. We performed a retrospective case-control study matching each SARS-CoV-2 positive patient (case) to a non-SARS-CoV-2 patient (control) treated in the same dialysis shift. Cases and controls were matched on age, sex, race, facility, shift date, and treatment count. For each case-control pair, we traced backward 14 days to assess possible prior exposure from a 'shedding' SARS-CoV-2 positive patient who sat in the same chair immediately before the case or control. Conditional logistic regression models tested whether chair exposure after a shedding SARS-CoV-2 positive patient conferred a higher risk of SARS-CoV-2 infection to the immediate subsequent patient., Results: Among 170,234 hemodialysis patients, 4,782 (2.8 %) tested positive for SARS-CoV-2 (mean age 64 years, 44 % female). Most facilities (68.5 %) had 0 to 1 positive SARS-CoV-2 patient. We matched 2,379 SARS-CoV-2 positive cases to 2,379 non-SARS-CoV-2 controls; 1.30 % (95 %CI 0.90 %, 1.87 %) of cases and 1.39 % (95 %CI 0.97 %, 1.97 %) of controls were exposed to a chair previously sat in by a shedding SARS-CoV-2 patient. Transmission risk among cases was not significantly different from controls (OR = 0.94; 95 %CI 0.57 to 1.54; p = 0.80). Results remained consistent in adjusted and sensitivity analyses., Conclusions: The risk of indirect patient-to-patient transmission of SARS-CoV-2 infection from dialysis chairs appears to be low., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
29. Real-time prediction of intradialytic relative blood volume: a proof-of-concept for integrated cloud computing infrastructure.
- Author
-
Chaudhuri S, Han H, Monaghan C, Larkin J, Waguespack P, Shulman B, Kuang Z, Bellamkonda S, Brzozowski J, Hymes J, Black M, Kotanko P, Kooman JP, Maddux FW, and Usvyat L
- Subjects
- Cloud Computing, Early Diagnosis, Female, Humans, Male, Middle Aged, Prognosis, Proof of Concept Study, Blood Volume physiology, Body Fluid Compartments, Hypotension diagnosis, Hypotension etiology, Hypotension prevention & control, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic therapy, Machine Learning, Muscle Cramp diagnosis, Muscle Cramp etiology, Muscle Cramp prevention & control, Renal Dialysis adverse effects, Renal Dialysis methods, Vomiting diagnosis, Vomiting etiology, Vomiting prevention & control
- Abstract
Background: Inadequate refilling from extravascular compartments during hemodialysis can lead to intradialytic symptoms, such as hypotension, nausea, vomiting, and cramping/myalgia. Relative blood volume (RBV) plays an important role in adapting the ultrafiltration rate which in turn has a positive effect on intradialytic symptoms. It has been clinically challenging to identify changes RBV in real time to proactively intervene and reduce potential negative consequences of volume depletion. Leveraging advanced technologies to process large volumes of dialysis and machine data in real time and developing prediction models using machine learning (ML) is critical in identifying these signals., Method: We conducted a proof-of-concept analysis to retrospectively assess near real-time dialysis treatment data from in-center patients in six clinics using Optical Sensing Device (OSD), during December 2018 to August 2019. The goal of this analysis was to use real-time OSD data to predict if a patient's relative blood volume (RBV) decreases at a rate of at least - 6.5 % per hour within the next 15 min during a dialysis treatment, based on 10-second windows of data in the previous 15 min. A dashboard application was constructed to demonstrate how reporting structures may be developed to alert clinicians in real time of at-risk cases. Data was derived from three sources: (1) OSDs, (2) hemodialysis machines, and (3) patient electronic health records., Results: Treatment data from 616 in-center dialysis patients in the six clinics was curated into a big data store and fed into a Machine Learning (ML) model developed and deployed within the cloud. The threshold for classifying observations as positive or negative was set at 0.08. Precision for the model at this threshold was 0.33 and recall was 0.94. The area under the receiver operating curve (AUROC) for the ML model was 0.89 using test data., Conclusions: The findings from our proof-of concept analysis demonstrate the design of a cloud-based framework that can be used for making real-time predictions of events during dialysis treatments. Making real-time predictions has the potential to assist clinicians at the point of care during hemodialysis., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
30. Hepatitis B Vaccination Response in Hemodialysis Patients: The Impact of Dialysis Shift.
- Author
-
Han M, Ye X, Rao S, Williams S, Thijssen S, Hymes J, Maddux FW, and Kotanko P
- Subjects
- Aged, Female, Humans, Kidney Failure, Chronic complications, Male, Middle Aged, Retrospective Studies, Vaccination, Vaccines, Synthetic therapeutic use, Hepatitis B prevention & control, Hepatitis B Vaccines therapeutic use, Kidney Failure, Chronic therapy, Renal Dialysis
- Abstract
Background/aims: Hepatitis B (HB) vaccination in hemodialysis patients is important as they are at a higher risk of contracting HB. However, hemodialysis patients have a lower HB seroconversion rate than their healthy counterparts. As better sleep has been associated with better seroconversion in healthy populations and early hemodialysis start has been linked to significant sleep-wake disturbances in hemodialysis patients, we examined if hemodialysis treatment start time is associated with HB vaccination response., Methods: Demographics, standard-of-care clinical, laboratory, and treatment parameters, dialysis shift data, HB antigen status, HB vaccination status, and HB titers were collected from hemodialysis patients in Fresenius clinics from January 2010 to December 2015. Patients in our analysis received 90% of dialysis treatments either before or after 8:30 a.m., were negative for HB antigen, and received a complete series of HB vaccination (Engerix B® or Recombivax HB™). Univariate and multivariate regression models examined whether dialysis start time is a predictor of HB vaccination response., Results: Patients were 65 years old, 57% male, and had a HD vintage of 10 months. Patients whose dialysis treatments started before 8:30 a.m. were more likely to be younger, male, and have a greater dialysis vintage. Patients receiving Engerix B® and starting dialysis before 8:30 a.m. had a significantly higher seroconversion rate compared to patients who started dialysis after 8:30 a.m. Early dialysis start was a significant predictor of seroconversion in univariate and multivariate regression including male gender, but not in multivariate regression including age, neutrophil-to-lymphocyte ratio, and vintage., Conclusion: While better sleep following vaccination is associated with seroconversion in the general population, this is not the case in hemodialysis patients after multivariate adjustment. In the context of end-stage kidney disease, early dialysis start is not a significant predictor of HB vaccination response. The association between objectively measured postvaccination sleep duration and seroconversion rate should be investigated., (© 2021 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
31. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
- Author
-
Thadhani R, Guilatco R, Hymes J, Maddux FW, and Ahuja A
- Subjects
- Adult, Aged, Aged, 80 and over, Algorithms, Anemia blood, Anemia etiology, Biosimilar Pharmaceuticals adverse effects, Dose-Response Relationship, Drug, Drug Dosage Calculations, Drug Substitution, Epoetin Alfa adverse effects, Female, Hematinics adverse effects, Hemoglobins analysis, Humans, Injections, Intravenous, Kidney Failure, Chronic blood, Kidney Failure, Chronic therapy, Male, Middle Aged, Renal Dialysis adverse effects, Retrospective Studies, Treatment Outcome, Young Adult, Anemia drug therapy, Biosimilar Pharmaceuticals administration & dosage, Epoetin Alfa administration & dosage, Hematinics administration & dosage, Kidney Failure, Chronic complications
- Abstract
Background: For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms. Using one such algorithm, we assessed the maintenance of hemoglobin levels in patients switched from epoetin alfa reference product (Epogen®) to epoetin alfa-epbx (RetacritTM; a biosimilar to US-licensed Epogen®/Procrit®)., Methods: This randomized, open-label, non-inferiority study was conducted at Fresenius Medical Care North America (FMCNA) hemodialysis centers. Patients with anemia and chronic kidney disease undergoing maintenance hemodialysis and receiving routine intravenous (IV) Epogen® were randomized 1: 1 to switch to IV RetacritTM or continue standard-of-care (Epogen®) for 24 weeks, using analogous versions of the FMCNA ESA-dosing algorithm. The primary endpoint was the proportion of time patients' hemoglobin was 9-11 g/dL during weeks 17-24., Results: Of 432 randomized patients, 418 received treatment (RetacritTM, n = 212; standard-of-care, n = 206) and comprised the full analysis set. A similar proportion of patients discontinued from each arm. The proportion of time patients' hemoglobin was within the target range was 61.9% (95% CI 57.5-66.2) in the RetacritTM arm and 63.3% (95% CI 58.7-67.7) in the standard-of-care arm. The difference in proportions between treatment arms was -1.4% (95% CI -7.6 to 4.9), and the lower bound of the confidence interval was within the pre-specified non-inferiority margin of -12.5%. There was no statistically significant difference between arms in the mean change from baseline in the weekly mean ESA dose during weeks 17-24, and no clinically relevant differences in safety outcomes., Conclusions: Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials.gov, NCT02504294)., (© 2018 The Author(s) Published by S. Karger AG, Basel.)
- Published
- 2018
- Full Text
- View/download PDF
32. Incident diabetic foot ulcers and mortality in hemodialysis patients.
- Author
-
Garimella PS, Wang W, Lin SF, Hymes J, and Lacson E Jr
- Published
- 2017
- Full Text
- View/download PDF
33. Conserved S-Layer-Associated Proteins Revealed by Exoproteomic Survey of S-Layer-Forming Lactobacilli.
- Author
-
Johnson BR, Hymes J, Sanozky-Dawes R, Henriksen ED, Barrangou R, and Klaenhammer TR
- Subjects
- Bacterial Proteins genetics, Bacterial Proteins metabolism, Lactobacillus chemistry, Lactobacillus classification, Lactobacillus metabolism, Lactobacillus acidophilus chemistry, Lactobacillus acidophilus genetics, Lactobacillus acidophilus metabolism, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Molecular Sequence Data, Phylogeny, Proteomics, Bacterial Proteins chemistry, Lactobacillus genetics, Membrane Glycoproteins chemistry
- Abstract
The Lactobacillus acidophilus homology group comprises Gram-positive species that include L. acidophilus, L. helveticus, L. crispatus, L. amylovorus, L. gallinarum, L. delbrueckii subsp. bulgaricus, L. gasseri, and L. johnsonii. While these bacteria are closely related, they have varied ecological lifestyles as dairy and food fermenters, allochthonous probiotics, or autochthonous commensals of the host gastrointestinal tract. Bacterial cell surface components play a critical role in the molecular dialogue between bacteria and interaction signaling with the intestinal mucosa. Notably, the L. acidophilus complex is distinguished in two clades by the presence or absence of S-layers, which are semiporous crystalline arrays of self-assembling proteinaceous subunits found as the outermost layer of the bacterial cell wall. In this study, S-layer-associated proteins (SLAPs) in the exoproteomes of various S-layer-forming Lactobacillus species were proteomically identified, genomically compared, and transcriptionally analyzed. Four gene regions encoding six putative SLAPs were conserved in the S-layer-forming Lactobacillus species but not identified in the extracts of the closely related progenitor, L. delbrueckii subsp. bulgaricus, which does not produce an S-layer. Therefore, the presence or absence of an S-layer has a clear impact on the exoproteomic composition of Lactobacillus species. This proteomic complexity and differences in the cell surface properties between S-layer- and non-S-layer-forming lactobacilli reveal the potential for SLAPs to mediate intimate probiotic interactions and signaling with the host intestinal mucosa., (Copyright © 2015 Johnson et al.)
- Published
- 2015
- Full Text
- View/download PDF
34. Anaphylaxis and hypotension after administration of peginesatide.
- Author
-
Bennett CL, Jacob S, Hymes J, Usvyat LA, and Maddux FW
- Subjects
- Anemia drug therapy, Humans, Renal Dialysis adverse effects, Anaphylaxis chemically induced, Hematinics adverse effects, Hypotension chemically induced, Peptides adverse effects
- Published
- 2014
- Full Text
- View/download PDF
35. Associates of cardiopulmonary arrest in the perihemodialytic period.
- Author
-
Flythe JE, Li NC, Lin SF, Brunelli SM, Hymes J, and Lacson E Jr
- Abstract
Cardiopulmonary arrest during and proximate to hemodialysis is rare but highly fatal. Studies have examined peridialytic sudden cardiac event risk factors, but no study has considered associates of cardiopulmonary arrests (fatal and nonfatal events including cardiac and respiratory causes). This study was designed to elucidate patient and procedural factors associated with peridialytic cardiopulmonary arrest. Data for this case-control study were taken from the hemodialysis population at Fresenius Medical Care, North America. 924 in-center cardiopulmonary events (cases) and 75,538 controls were identified. Cases and controls were 1 : 5 matched on age, sex, race, and diabetes. Predictors of cardiopulmonary arrest were considered for logistic model inclusion. Missed treatments due to hospitalization, lower body mass, coronary artery disease, heart failure, lower albumin and hemoglobin, lower dialysate potassium, higher serum calcium, greater erythropoietin stimulating agent dose, and normalized protein catabolic rate (J-shaped) were associated with peridialytic cardiopulmonary arrest. Of these, lower albumin, hemoglobin, and body mass index; higher erythropoietin stimulating agent dose; and greater missed sessions had the strongest associations with outcome. Patient health markers and procedural factors are associated with peridialytic cardiopulmonary arrest. In addition to optimizing nutritional status, it may be prudent to limit exposure to low dialysate potassium (<2 K bath) and to use the lowest effective erythropoietin stimulating agent dose.
- Published
- 2014
- Full Text
- View/download PDF
36. Sodium thiosulfate therapy for calcific uremic arteriolopathy.
- Author
-
Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, and Lacson E Jr
- Subjects
- Administration, Intravenous, Adult, Aged, Calciphylaxis diagnosis, Calciphylaxis mortality, Chi-Square Distribution, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Remission Induction, Thiosulfates administration & dosage, Thiosulfates adverse effects, Time Factors, Treatment Outcome, Calciphylaxis drug therapy, Thiosulfates therapeutic use
- Abstract
Background and Objective: Calcific uremic arteriolopathy (CUA) is an often fatal condition with no effective treatment. Multiple case reports and case series have described intravenous sodium thiosulfate (STS) administration in CUA, but no studies have systematically evaluated this treatment., Design, Setting, Participants, & Measurements: This study included 172 patients undergoing maintenance hemodialysis who had CUA and were treated with STS between August 2006 and June 2009 at Fresenius Medical Care North America. Of these, 85% completed STS therapy. Clinical, laboratory, and mortality data were abstracted from clinical information systems. Responses to survey questionnaires sent to treating physicians regarding patient-level outcomes were available for 53 patients. Effect on CUA lesions and mortality were summarized as CUA outcomes. Relevant laboratory measures, weight (using pairwise comparisons of values before, during, and after STS), and adverse events were summarized as safety parameters., Results: Mean age of the cohort was 55 years, and 74% of patients were women. Median STS dose was 25 g, and median number of doses was 38. Among surveyed patients, CUA completely resolved in 26.4%, markedly improved in 18.9%, improved in 28.3%, and did not improve in 5.7%; in the remaining patients (20.8%), the response was unknown. One-year mortality in patients treated with STS was 35%. Adverse events, laboratory abnormalities, and weight-related changes were mild. Significant reductions in serum phosphorous (P=0.02) and parathyroid hormone (P=0.01) were noted during STS treatment in patients who completed the therapy., Conclusions: Although conclusive evidence regarding its efficacy is lacking, a majority of patients who received STS demonstrated clinical improvement in this study.
- Published
- 2013
- Full Text
- View/download PDF
37. Identification of alternatively spliced human biotinidase mRNAs and putative localization of endogenous biotinidase.
- Author
-
Stanley CM, Hymes J, and Wolf B
- Subjects
- 5' Flanking Region, Amino Acid Sequence, Animals, Base Sequence, Biotinidase metabolism, Blotting, Western, Cells, Cultured, Chromosome Mapping, Female, Humans, Liver enzymology, Liver metabolism, Liver ultrastructure, Microscopy, Electron, Mitochondria genetics, Mitochondria metabolism, Mitochondria ultrastructure, Molecular Sequence Data, Molecular Weight, RNA, Messenger genetics, Rats, Rats, Sprague-Dawley, Alternative Splicing, Biotinidase genetics, RNA, Messenger metabolism
- Abstract
Biotinidase is essential for recycling the vitamin biotin and for transferring biotin to proteins, such as histones, suggesting that the enzyme localizes to various cellular and extracellular sites. To better understand the functions of the enzyme, we examined its gene structure and subcellular localization. Using RACE-PCR and a BLAST search, we extended the 5' sequence of the biotinidase gene. Three novel, alternatively spliced variants of biotinidase, 1a, 1b, and 1c, were identified in multiple human tissues. Exon 1c is present only in testes. The sequence of the 5' splice variants, 1a and 1b, suggest that biotinidase localizes to the mitochondria and/or ER, respectively. Using indirect immunofluorescence studies, biotinidase localizes to organelles in the cytoplasm, but not nucleus, of human fibroblasts and Hep G2 cells. Endogenous expression was examined by isopycnic gradient centrifugation of rat liver organelles, which identified an 85kDa biotinidase protein with biotinyl-hydrolase and transferase activities in microsomes and possibly lysosomes. A 48kDa protein, which also reacts with anti-biotinidase, localizes to mitochondria. The 48kDa protein is not N-glycosylated but is biotinylated, is in the inner mitochondrial matrix, but has no biotinyl-hydrolase or transferase activities. The function and validation of the mitochondrial species remains to be determined. The 5' splice variants and organelle fractionation studies indicate that biotinidase is directed to the secretory pathway and perhaps mitochondria.
- Published
- 2004
- Full Text
- View/download PDF
38. Mutations in BTD causing biotinidase deficiency.
- Author
-
Hymes J, Stanley CM, and Wolf B
- Subjects
- Alleles, Biotinidase, Chromosomes, Human, Pair 3 genetics, Exons genetics, Gene Frequency genetics, Genetic Testing, Humans, Introns genetics, Polymorphism, Genetic genetics, Amidohydrolases deficiency, Amidohydrolases genetics, Mutation genetics
- Abstract
Biotinidase (BTD) is the only enzyme that can cleave biocytin, a product of the proteolytic digestion of holocarboxylases. Profound BTD deficiency (less than 10% mean normal activity in serum) is an autosomal recessive disorder that can result in neurological and cutaneous abnormalities. Both the cDNA and the genomic DNA of normal BTD gene have been isolated and characterized. The BTD gene is localized to chromosome 3p25. Thus far 61 mutations in three of the four exons of the BTD and one mutation in an intron gene that cause profound BTD deficiency have been reported. Mutations occur at different frequencies in symptomatic children than they do in children ascertained by newborn screening. Two mutations, 98-104del7ins3 and R538C, were present in 52% or 31 of 60 alleles found in symptomatic patients. Three other mutations, A755G, Q456H, and 511 G>A; 1330G>C (double mutation), accounted for 52% of the alleles detected by newborn screening in the United States. Two asymptomatic adults, parents of children with profound BTD deficiency detected by newborn screening, have been described. Additional different mutations have been found in Turkish, Saudi Arabian, and Japanese children with profound BTD deficiency. Partial BTD deficiency (10-30% of mean normal serum activity) is predominantly caused by the single 1330G>C mutation that results in D444H on one allele in combination with one of the mutations causing profound deficiency on the other allele. Four intragenic polymorphisms, three neutral and one amino acid change, have also been found. Although a preponderance of mutations causing the production of truncated BTD protein occurs in symptomatic children with profound deficiency, preliminary studies fail to demonstrate clear genotype-phenotype correlations., (Copyright 2001 Wiley-Liss, Inc.)
- Published
- 2001
- Full Text
- View/download PDF
39. Examination of the signal peptide region of human biotinidase using a baculovirus expression system.
- Author
-
Norrgard KJ, Hymes J, and Wolf B
- Subjects
- Amidohydrolases chemistry, Amino Acid Sequence, Animals, Baculoviridae genetics, Biological Transport, Biotinidase, Cell Line, Codon, Initiator genetics, Culture Media, Conditioned, Glycosylation, Humans, Molecular Sequence Data, Molecular Weight, Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase, Protein Sorting Signals chemistry, Protein Sorting Signals genetics, RNA, Messenger genetics, Recombinant Proteins biosynthesis, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Spodoptera cytology, Spodoptera virology, Amidohydrolases genetics, Amidohydrolases metabolism, Baculoviridae metabolism, Gene Expression, Protein Biosynthesis genetics, Protein Sorting Signals physiology
- Abstract
Biotinidase deficiency is an autosomal recessive disorder of biotin recycling. Biotinidase cleaves the biotin from biocytin or short biotinyl-peptides to replenish the free biotin pool, or it can transfer the vitamin to specific proteins. The cDNA for human serum biotinidase has two in-frame start codons, potentially allowing for the synthesis of an enzyme with a signal peptide (SP) consisting of either 21 or 41 amino acids. In order to examine the requirements of the signal peptide region for the production and secretion of biotinidase, three different forms of the normal human serum biotinidase gene were constructed that encode either the 21-amino-acid SP (SP21-NL) or the 41-amino-acid SP (SP41-NL) or without a SP (NoSP-NL). These constructs were expressed in insect cells via a baculovirus expression system. Biotinidase from cells with SP41-NL and SP21-NL had immunoreactive and biotinyl-hydrolase-active enzyme in lysates and expression media. Cells with NoSP-NL had about 3% of the immunoreactive material and no enzyme activity in lysates and no immunoreactive protein or enzymatic activity in the expression medium. Lack of biotinidase from cells with NoSP-NL may be due to translation inefficiency or increased susceptibility of this species to protease degradation than the secreted forms. We have demonstrated that the 21-amino-acid signal peptide is sufficient to result in glycosylated, secreted biotinidase, but we cannot determine if the glycosylated biotinidase in the lysates or secreted in the medium of cells with SP41-NL use the first, second, or both ATGs in the SP region. Because this particular expression system has no mechanism for timing the movement of newly translated biotinidase protein, we cannot draw conclusions about the relative efficiency of SP41-NL versus SP21-NL, but it is possible that either is used in vivo depending on particular cellular conditions., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF
40. Mutations causing profound biotinidase deficiency in children ascertained by newborn screening in the United States occur at different frequencies than in symptomatic children.
- Author
-
Norrgard KJ, Pomponio RJ, Hymes J, and Wolf B
- Subjects
- Amino Acid Substitution, Biotinidase, Frameshift Mutation, Humans, Infant, Newborn, Multiple Carboxylase Deficiency epidemiology, Multiple Carboxylase Deficiency genetics, Point Mutation, Polymerase Chain Reaction, United States epidemiology, Amidohydrolases deficiency, Amidohydrolases genetics, Genetic Testing, Multiple Carboxylase Deficiency diagnosis, Mutation, Neonatal Screening
- Abstract
Biotinidase deficiency is an autosomal recessive disorder of biotin metabolism that can lead to varying degrees of neurologic and cutaneous symptoms when untreated. Because this disorder meets the criteria for newborn screening, many states and countries perform this testing. Because newborn screening should result in complete ascertainment of mutations causing profound biotinidase deficiency (less than 10% of mean normal serum activity), we compared the mutations in a group of 59 children with profound biotinidase deficiency who were identified by newborn screening in the United States with 33 children ascertained by exhibiting symptoms. Of the 40 total mutations identified among the two populations, four mutations comprise 59% of the disease alleles studied. Two of these mutations occur in both populations, but in the symptomatic group at a significantly greater frequency. The other two common mutations occur only in the newborn screening group. Because two common mutations do not occur in the symptomatic population, it is possible that individuals with these mutations either develop mild or no symptoms if left untreated. However, inasmuch as biotin treatment is inexpensive and innocuous, it is still recommended that all children with profound biotinidase deficiency be treated.
- Published
- 1999
- Full Text
- View/download PDF
41. Mutation in a putative glycosylation site (N489T) of biotinidase in the only known Japanese child with biotinidase deficiency.
- Author
-
Pomponio RJ, Yamaguchi A, Arashima S, Hymes J, and Wolf B
- Subjects
- Amidohydrolases blood, Amino Acid Substitution, Asparagine genetics, Binding Sites genetics, Biotinidase, Child, DNA Mutational Analysis, Glycosylation, Homozygote, Humans, Japan, Male, Mutation genetics, Threonine genetics, Amidohydrolases deficiency, Amidohydrolases genetics
- Abstract
The only known Japanese child with biotinidase deficiency was identified by newborn screening in Japan. He has 10.8% of mean normal serum biotinyl-hydrolase activity and trace biotinyl-transferase activity. The mutation results in 16% of normal cross-reacting material in serum with antibody to purified normal biotinidase. He is homozygous for a unique mutation, A1466 > C (Asn489Thr) in exon 4 of the biotinidase gene. The mutation appears to abolish a putative glycosylation site in a region in which other missense mutations have been identified, indicating that this region of the enzyme must be important for enzyme activity. This mutation may affect secretion or stability of the enzyme in serum. Interestingly, this child is now 8 years old, has not been on biotin supplementation for 3 years, and has remained asymptomatic., (Copyright 1998 Academic Press.)
- Published
- 1998
- Full Text
- View/download PDF
42. Double mutation (A171T and D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening the the United States. Mutations in brief no. 128. Online.
- Author
-
Norrgard KJ, Pomponio RJ, Swango KL, Hymes J, Reynolds T, Buck GA, and Wolf B
- Subjects
- Acyltransferases genetics, Alanine genetics, Aspartic Acid genetics, Histidine genetics, Humans, Infant, Newborn, Threonine genetics, Acyltransferases deficiency, Mutation genetics, Neonatal Screening
- Abstract
Biotinidase deficiency is inherited as an antosomal recessive trait that, unless treated with pharmacologic doses of biotin, can result in neurologic and cutaneous symptoms. We have identified two new mutations in exon D of the biotinidase gene of children with profound biotinidase deficiency ascertained by newborn screening. Transition 511G->A near the 5' end of exon D results in a substitution of threonine for alanine 171 (A171T) and transversion 1330G->C occurs close to the 3' end of exon D causing a substitution of histidine for aspartic acid 444 (D444H). The D444H mutation was detected in four individuals from our normal population whose mean serum biotinidase activity is 5.25 nmol/min/ml, which is significantly lower than the mean normal activity (7.1 nmol/min/ml). We calculated that this mutation causes a 52% loss of activity in the aberrant enzyme. Twenty-three individuals with the D444H mutation were found by allele specific oligonucleotide analysis of DNA from 296 randomly-selected, anonymous dried-blood spots. We estimate the frequency of this allele in the general population to be 0.039. In contrast, no individuals in 376 have the A171T mutation. Fourteen children (eleven probands and three siblings) out of the 31 enzyme-deficient children have both the A171T and D444H mutations. Both mutations are inherited from a single parent as a double mutation allele. The nine families in which this allele was identified are of mostly European ancestry, although the mutation cannot be attributed to a specific nationality or ethnic group. The serum of a child who is homozygous for the double mutation allele has very little CRM and the aberrant enzyme has very low biotinylhydrolase activity and no botinyl-transferase activity. This double mutation allele (A171T and D444H) is a common cause of profound biotinidase deficience in children ascertained by newborn screening in the United States.
- Published
- 1998
- Full Text
- View/download PDF
43. Mutations in the human biotinidase gene that cause profound biotinidase deficiency in symptomatic children: molecular, biochemical, and clinical analysis.
- Author
-
Pomponio RJ, Hymes J, Reynolds TR, Meyers GA, Fleischhauer K, Buck GA, and Wolf B
- Subjects
- Acyltransferases blood, Acyltransferases deficiency, Amidohydrolases blood, Amidohydrolases deficiency, Biotinidase, Child, Genetic Testing, Genotype, Humans, Mutation, Phenotype, Sequence Analysis, DNA, Acyltransferases genetics, Amidohydrolases genetics
- Abstract
Biotinidase deficiency is an autosomal recessively inherited disorder that results in the inability to recycle the vitamin biotin. The disorder can cause neurologic and cutaneous abnormalities that can be treated effectively with pharmacologic doses of biotin. We identified 21 mutations that cause profound biotinidase deficiency in 37 symptomatic children (30 different probands and 7 siblings), as well as provide relevant biochemical and clinical information for each child. The two most common mutations (G98:d7i3 and R538C) were found in 31 of 60 alleles (52%), whereas the remainder of the alleles are accounted for by the 19 other unique mutations. Serum samples were available from 18 children, of these 11 had no detectable cross-reacting material (CRM) to antibody prepared against normal human serum biotinidase, three had reduced quantities of CRM and four had normal quantities of CRM in serum. All of these mutations result in complete absence of biotinyl-transferase activity in serum. Two polymorphisms were also identified in normal individuals. It is apparent that a child who inherits any of these mutations, either in the homozygous state or in combination, can develop the clinical features of the disorder if untreated. There are, however, no clear genotype/phenotype correlations that would allow for the prediction of the type, severity, or age of onset of symptoms.
- Published
- 1997
- Full Text
- View/download PDF
44. Profound biotinidase deficiency in two asymptomatic adults.
- Author
-
Wolf B, Norrgard K, Pomponio RJ, Mock DM, McVoy JR, Fleischhauer K, Shapiro S, Blitzer MG, and Hymes J
- Subjects
- Adult, Biotin blood, Biotin urine, Biotinidase, Female, Humans, Lysine analogs & derivatives, Lysine blood, Lysine urine, Male, Amidohydrolases deficiency
- Abstract
Biotinidase deficiency is an autosomal-recessive disorder of biotin recycling. Children with profound biotinidase deficiency usually have neurological and cutaneous symptoms in early childhood, but they may not develop symptoms until adolescence. We now report on a man and a woman with profound biotinidase deficiency who are asymptomatic and who were diagnosed only because their biotinidase-deficient children were identified by newborn screening. These adults have never exhibited symptoms of the disorder and are homozygous for two different mutations resulting in different aberrant enzymes. There is no evidence of an increased dietary intake of biotin to explain why they have remained asymptomatic. Although these adults may still be at risk for developing symptoms, they could represent a small group of individuals with profound biotinidase deficiency who will never develop clinical problems. Their lack of symptoms suggests that there are probably epigenetic factors that protect some enzyme-deficient individuals from developing symptoms. These individuals broaden the spectrum of expression of biotinidase deficiency.
- Published
- 1997
- Full Text
- View/download PDF
45. Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States.
- Author
-
Norrgard KJ, Pomponio RJ, Swango KL, Hymes J, Reynolds TR, Buck GA, and Wolf B
- Subjects
- Acyltransferases metabolism, Adult, Amidohydrolases immunology, Biotinidase, Genetic Testing, Humans, Infant, Newborn, United States, Amidohydrolases deficiency, Amidohydrolases genetics, Neonatal Screening, Point Mutation genetics
- Abstract
Biotinidase deficiency is an autosomal recessive disorder that can result in neurologic and cutaneous symptoms if not treated with biotin supplementation. We have identified the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. 1368A-->C results in a substitution of histidine for glutamine 456 (Q456H) in exon D of the biotinidase gene. This mutation was found in at least one allele in 14 unrelated children from 27 different families or 15 of 54 alleles studied (28%). This mutation was not identified in 41 normal adults using SSCA, nor was it found in 296 normal newborns using allele-specific oligonucleotide analysis, suggesting that this change is not a polymorphism. In addition, biochemical data from a child homozygous for Q456H suggest that the aberrant enzyme has very low biotinyl-hydrolase activity, lacks biotinyl-transferase activity, and is not recognized by antibody prepared to purified, normal human biotinidase. The ethnic backgrounds of the parents contributing the Q456H allele are varied but are generally northern European.
- Published
- 1997
- Full Text
- View/download PDF
46. Arg538 to Cys mutation in a CpG dinucleotide of the human biotinidase gene is the second most common cause of profound biotinidase deficiency in symptomatic children.
- Author
-
Pomponio RJ, Norrgard KJ, Hymes J, Reynolds TR, Buck GA, Baumgartner R, Suormala T, and Wolf B
- Subjects
- Acyltransferases deficiency, Acyltransferases metabolism, Alleles, Amidohydrolases deficiency, Amidohydrolases immunology, Amidohydrolases metabolism, Antibodies immunology, Arginine, Automation, Biotin, Biotinidase, Cells, Cultured, Child, Cysteine, DNA, Exons, Female, Fibroblasts cytology, Humans, Male, Pedigree, Sequence Analysis, DNA, Acyltransferases genetics, Amidohydrolases genetics, Dinucleoside Phosphates genetics, Point Mutation
- Abstract
Biotinidase deficiency is an autosomal recessively inherited disorder in the recycling of the vitamin biotin. The most common mutation that causes profound biotinidase deficiency in symptomatic individuals is a deletion/insertion (G98:d7i3) that occurs in exon B of the biotinidase gene. We now report the second most common mutation, a C-to-T substitution (position 1612) in a CpG dinucleotide in exon D of the biotinidase gene. This mutation results in the substitution of a cysteine for arginine538 (designated R538C) and was found in 10 of 30 symptomatic children with profound biotinidase deficiency, 5 of whom also have the G98:d7i3 mutation. This mutation was not found in DNA samples from 32 individuals with normal biotinidase activity, but was found in one individual with enzyme activity in the heterozygous range. This mutation was not detected in 371 randomly selected, normal individuals using allele-specific oligonucleotide hybridization analysis. Aberrant biotinidase protein was not detectable in extracts of fibroblasts from a child who is homozygous for the R538C mutation, but was present in less than normal concentration in identical extracts treated with beta-mercaptoethanol. Because there is no detectable biotinidase protein in sera of children who are homozygous for the R538C mutation and in combination with the deletion/insertion mutation, the R538C mutation likely results in inappropriate intra- or intermolecular disulfide bond formation, more rapid degradation of the aberrant enzyme, and failure to secrete the residual aberrant enzyme from the cells into blood.
- Published
- 1997
- Full Text
- View/download PDF
47. Biotinidase in serum and tissues.
- Author
-
Hymes J, Fleischhauer K, and Wolf B
- Subjects
- Amidohydrolases analysis, Animals, Biotinidase, Humans, Amidohydrolases metabolism
- Published
- 1997
- Full Text
- View/download PDF
48. Biochemical and immunologic characterization of serum biotinidase in partial biotinidase deficiency.
- Author
-
Hart PS, Hymes J, and Wolf B
- Subjects
- Adult, Amidohydrolases blood, Amidohydrolases immunology, Biotinidase, Cross Reactions, Female, Humans, Immunochemistry, Infant, Newborn, Isoelectric Focusing, Kinetics, Male, Phenotype, Amidohydrolases deficiency
- Abstract
Newborn screening for biotinidase deficiency has identified children with profound biotinidase deficiency (less than 10% of mean normal activity) and about an equal number of children with partial biotinidase deficiency (10 to 30% of mean normal activity). Partial biotinidase deficiency was initially considered a variant without clinical consequences until one child, during an episode of gastroenteritis, developed symptoms of biotinidase deficiency that resolved with biotin therapy. Biochemical and immunologic characterization of biotinidase was performed in sera from 23 children with partial biotinidase deficiency from 19 families and 18 of their parents. As expected, all patients had cross-reacting material in their serum. Patients with partial biotinidase deficiency can be classified into six distinct biochemical phenotypes on the basis of the number of isoforms and the distribution frequency of the isoforms. Kinetic studies were performed on samples from 17 of the patients and were found to be normal in all cases. The patient with partial deficiency who became symptomatic has an isoform profile that is not different from 10 other asymptomatic, partially deficient children. The parents had normal isoform patterns. The isoform patterns observed in the patients with partial biotinidase deficiency were not different from those of the profoundly deficient patients who had cross-reacting material.
- Published
- 1992
- Full Text
- View/download PDF
49. Isoforms of human serum biotinidase.
- Author
-
Hart PS, Hymes J, and Wolf B
- Subjects
- Adult, Amidohydrolases deficiency, Biotinidase, Blotting, Western, Child, Electrophoresis, Polyacrylamide Gel, Female, Glycoside Hydrolases metabolism, Humans, Isoelectric Point, Male, Neuraminidase metabolism, Amidohydrolases blood, Isoenzymes blood
- Published
- 1991
- Full Text
- View/download PDF
50. Biotinidase.
- Author
-
Wolf B, Hymes J, and Heard GS
- Subjects
- Amidohydrolases analysis, Animals, Biotinidase, Carbon Radioisotopes, Humans, Indicators and Reagents, Kinetics, Radioisotope Dilution Technique, Spectrophotometry methods, Substrate Specificity, Amidohydrolases metabolism
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.